Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Nov 27;39(12):2016-2024.
doi: 10.1093/ndt/gfae092.

Interactive exploration of adverse events and multimorbidity in CKD

Collaborators, Affiliations
Observational Study

Interactive exploration of adverse events and multimorbidity in CKD

Inga Steinbrenner et al. Nephrol Dial Transplant. .

Abstract

Background: Persons with chronic kidney disease (CKD) are at increased risk of adverse events, early mortality and multimorbidity. A detailed overview of adverse event types and rates from a large CKD cohort under regular nephrological care is missing. We generated an interactive tool to enable exploration of adverse events and their combinations in the prospective, observational German CKD (GCKD) study.

Methods: The GCKD study enrolled 5217 participants under regular nephrological care with an estimated glomerular filtration rate of 30-60 or >60 mL/min/1.73 m2 and an overt proteinuria. Cardiovascular, cerebrovascular and peripheral vascular, kidney, infection, and cancer events, as well as deaths were adjudicated following a standard operation procedure. We summarized these time-to-event data points for exploration in interactive graphs within an R shiny app. Multivariable adjusted Cox models for time to first event were fitted. Cumulative incidence functions, Kaplan-Meier curves and intersection plots were used to display main adverse events and their combinations by sex and CKD etiology.

Results: Over a median of 6.5 years, 10 271 events occurred in 2947 participants (56.5%), of which 680 participants (13.0%) died. The new publicly available interactive platform enables readers to scrutinize adverse events and their combinations as well as mortality trends as a gateway to better understand multimorbidity in CKD: incident rates per 1000 patient-years varied by event type, CKD etiology and baseline characteristics. Incidence rates for the most frequent events and their recurrence were 113.6 (cardiovascular), 75.0 (kidney) and 66.0 (infection). Participants with presumed diabetic kidney disease and men were more prone to experiencing events.

Conclusion: This comprehensive explorative tool to visualize adverse events (https://www.gckd.org/studienhintergrund/previous-study-results/event-analysis/), their combination, mortality and multimorbidity among persons with CKD may serve as a valuable resourec for patient care, identification of high-risk groups, health services and public health policy planning.

Keywords: adverse events; chronic kidney disease; epidemiology; interactive visualization; multimorbidity.

PubMed Disclaimer

Conflict of interest statement

The following conflict of interest statement is taken from the indication in the conflict of interest forms of each co-author. E.S. received consulting fees from AstraZeneca, honoraria, as a speaker from the National Kidney Foundation, is a board member of German Society of Nephrology and a KDIGO Working group. J.T.K. is stockholder with Synlab, BAYER and Quanterix Inc. J.F. received consulting fees and honoraria as a speaker from AstraZeneca, BAYER, Boehringer, CSL Vifor, Stadapharm, and Travere. C.W. received research grants for the institution from Boehringer Ingelheim, Sanofi and consulting fees from Amgen, Amicus, Astellas, AstraZeneca, BAYER, Boehringer Ingelheim, CSL Vifor, Chiesi, Chugai, Fresenius Medical Care, GSK, Idorsia, Eli Lilly, MSD, Novartis, Novo Nordisk, and Sanofi. A.K. received grant funding by the German Research Foundation (DFG) project ID 431984000 (SFB 1453) for the Institute of Genetic Epidemiology Freiburg. M.B. received consulting fees from Vifor Renal Pharma, Boehringer Ingelheim and honoraria as a speaker from AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis Pharma, support for meeting registration/travel from Alexion Pharma. K.U.E. received grant funding from Evotec, Travere, AstraZeneca, consulting fees from Akebia, AstraZeneca, BAYER, Otsuka, Retrophin. J.M. received honoraria as a speaker from AstraZeneca, Boehringer Ingelheim, BAYER, Alexion, Lilly. The remaining authors disclosed no conflicts of interest.

Figures

Figure 1:
Figure 1:
Kaplan–Meier survival curve for all-cause mortality by sex and primary cause of kidney disease. Solid lines represent male (m) participants, dashed lines female (f) participants. Green: DKD as presumed primary cause of kidney disease; blue: HKD as presumed primary cause of kidney disease; red: PGD as presumed primary kidney disease; black: MISC = any other primary cause of kidney disease. Men diagnosed with DKD had the highest risk of death; women with DKD had a similar risk of death as men with HKD. Men with PGD were at similar risk of death as women with either HKD or MISC. Women with PGD had the lowest risk of death.
Figure 2:
Figure 2:
Intersection plot of main adverse event categories and their combinations after 6.5 years of follow-up. Main event categories: cardiovascular (“A”), cerebrovascular (“B”), peripheral arterial occlusive disease (PAOD, “C”), kidney (“E”), death (“F”), cancer (“G”), infection (“H”). Plots include recurrent events. Colored intersection plot: indicates intersection of event combinations in main event categories, e.g. 176 participants experienced a combination of adverse kidney events and infection events until the end of the follow-up period, while a total of 787 participants experienced adverse events in two event categories overall. Stacked barplot: number of participants in each intersection by sex. Colored barplot: number of participants with events of a main event category is plotted. *Total number of participants with events in one to five event categories. Intersections with fewer than 11 participants are not shown here. In total, 11 participants had events in six event categories.
Figure 3:
Figure 3:
Cumulative incidence function for kidney failure by sex for KDIGO eGFR and/or UACR categories. Panel (A) by eGFR categories (G1–5), panel (B) by UACR categories (A1–3), (C) combined eGFR and UACR categories. Green: low-risk categories (G1/2A1), yellow: medium-risk categories (G3aA1, G1/2A2, orange: medium-high risk (G3bA1, G3aA2, G1/2A3) and red: high risk categories (G3aA3, G3bA2/3, G4A1–3, G5A1–3). m = men, solid lines; f = women, dashed lines.
Figure 4:
Figure 4:
Cumulative incidence function for myocardial infarction by sex for KDIGO eGFR and/or UACR categories. Panel (A) by eGFR categories (G1–5), (B) by UACR categories (A1–3), (C) combined eGFR and UACR categories. Green: low-risk categories, yellow: medium-risk categories, orange: medium-high risk and red: high risk categories. m = men, solid lines; f = women, dashed lines.

References

    1. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150. - PubMed
    1. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709–33. 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Stel VS, Brück K, Fraser S et al. International differences in chronic kidney disease prevalence: a key public health and epidemiologic research issue. Nephrol Dial Transplant 2017;32:ii129–35. 10.1093/ndt/gfw420 - DOI - PubMed
    1. Bruck K, Stel VS, Gambaro G et al. CKD prevalence varies across the European general population. J Am Soc Nephrol 2016;27:2135–47. 10.1681/ASN.2015050542 - DOI - PMC - PubMed
    1. Webster AC, Nagler EV, Morton RL et al. Chronic kidney disease. Lancet 2017;389:1238–52. 10.1016/S0140-6736(16)32064-5 - DOI - PubMed

Publication types

LinkOut - more resources